Skip to main content

Table 3 PsA treatment at study visit

From: Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study

 

Total

MDA

No MDA

p

Treatment pattern, n (%)

   

NS

 Anti-TNF monotherapy

110

69 (62.7)

41 (37.3)

 

 DMARDS and anti-TNF

61

32 (52.5)

29 (47.5)

 

 DMARDS monotherapy

51

32 (62.7)

19 (37.3)

 

Anti-TNF*, n (%)

112

64 (57.1)

48 (42.9)

NS

 Etanercept

42

26 (61.9)

16 (38.1)

 

 Adalimumab

35

22 (62.9)

13 (37.1)

 

 Infliximab

15

6 (40.0)

9 (60.0)

 

 Golimumab

13

7 (53.8)

6 (46.2)

 

 Mean (SD) time, months

45.7 (34.7)

50.5 (35.0)

40.2 (33.8)

NS

DMARDS*, n (%)

171

101 (59.1)

70 (40.9)

NS

 Metotrexate

130

76 (58.5)

54 (41.5)

 

 Leflunomide

32

17 (53.1)

15 (46.9)

 

 Mean (SD) time, months

73.7 (70.4)

71.8 (71.8)

76.4 (69.7)

NS

NSAIDs**, n (%)

114

62 (54.4)

52 (45.6)

NS

Infiltrations**, n (%)

48

27 (56.3)

21 (43.8)

NS

Corticoids**, n (%)

39

16 (41.0)

23 (59.0)

<0.05

  1. *Monotherapy or combination therapy
  2. **Combination therapy
  3. anti-TNF anti-tumor necrosis factor, DMARDS disease-modifying anti-rheumatic drugs, NS not significant, NSAIDs nonsteroidal anti-inflammatory drugs